Active substanceAcyclovirAcyclovir
Similar drugsTo uncover
  • Acigerpine
    cream externally 
  • Acyclovir
    pills inwards 
    AVVA RUS, OJSC     Russia
  • Acyclovir
    cream externally 
    ATOLL, LLC     Russia
  • Acyclovir
    lyophilizate in / in 
    ALVILS, LTD.     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir
    cream locally externally 
    VERTEKS, AO     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir
    ointment locally externally 
    OZONE, LLC     Russia
  • Acyclovir
    pills inwards 
    AVEKSIMA, JSC     Russia
  • Acyclovir
    ointment externally 
  • Acyclovir
    lyophilizate in / in d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Acyclovir
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Acyclovir
    ointment externally 
  • Acyclovir
    ointment d / eye 
    SYNTHESIS, OJSC     Russia
  • Acyclovir
    ointment externally 
    VERTEKS, AO     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir
    ointment externally 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Acyclovir
    ointment locally externally 
    ALVILS, LTD.     Russia
  • Acyclovir
    ointment locally externally 
    AZT PHARMA KB, LLC     Russia
  • Acyclovir
    ointment externally 
    NIZHFARM, JSC     Russia
  • Acyclovir
    ointment externally 
    ALTAYVITAMINS, CJSC     Russia
  • Acyclovir
    pills inwards 
    NIZHFARM, JSC     Russia
  • Acyclovir
    pills inwards 
    OZONE, LLC     Russia
  • Acyclovir
    ointment externally 
  • Acyclovir
    pills inwards 
    OZONE, LLC     Russia
  • Acyclovir
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Acyclovir
    ointment externally 
    GREEN DUBRAVA, CJSC     Russia
  • Acyclovir
    pills inwards 
  • Acyclovir Belupo
    cream externally 
  • Acyclovir Belupo
    pills inwards 
  • Acyclovir Sandoz®
    pills inwards 
    Sandoz d.     Slovenia
  • Acyclovir Sandoz®
    cream externally 
    Sandoz d.     Slovenia
  • Acyclovir forte
    pills inwards 
  • Acyclovir-AKOS
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Acyclovir-Abrichin
    ointment externally 
    AKRIKHIN HFK, JSC     Russia
  • Acyclovir-Ferein
    cream externally 
    BRYNTSALOV-A, CJSC     Russia
  • Acyclostad®
    pills inwards 
  • Vivorax
    cream externally 
  • Vivorax
    pills inwards 
  • Virollex
    cream externally 
  • Virollex
    lyophilizate d / infusion 
  • Gervirax
    cream externally 
  • Gerperax
    ointment externally 
  • Gerperax
    pills inwards 
  • Zovirax ®
    lyophilizate d / infusion 
  • Zovirax ®
    ointment d / eye 
  • Zovirax ®
    pills inwards 
  • Zovirax ®
    cream externally 
  • Medovir
    powder d / infusion 
    Medocemi Co., Ltd.     Cyprus
  • Provirsan®
    pills inwards 
    PRO.MED.CS Prague as.     Czech Republic
  • Dosage form: & nbsplyophilizate for solution for infusion
    Composition:

    Composition per 1 bottle:

    Active substance: Acyclovir 250.00 mg

    Excipient: sodium hydroxide - about 45 mg.

    Description:Porous compact mass or powder of white or almost white color.
    Pharmacotherapeutic group:Antiviral agent
    ATX: & nbsp

    S.01.A.D   Antiviral drugs

    Pharmacodynamics:

    Mechanism of action

    Acyclovir is a synthetic analogue of a purine nucleoside, which has the ability to inhibit in vitro and in vivo human herpes viruses, including herpes simplex virus (HSV) Type 1 and type 2, varicella and herpes zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV). In cell culture acyclovir has the most pronounced antiviral activity against HSV-1, then in order of decreasing activity follows: HSV-2, VZV (varicella zoster virus, Varicella zoster virus), EBV and CMV.

    The effect of acyclovir on herpes viruses (HSV-1, HSV-2, VZV, EBV, CMV) is highly selective. Acyclovir is not a substrate for the enzyme thymidine kinase of uninfected cells, therefore acyclovir low toxicity for mammalian cells. Thymidine kinase of cells infected with TIG, VBW, EBV and CMV viruses converts acyclovir in acyclovir monophosphate - an analogue of a nucleoside, which is then subsequently converted into a diphosphate and triphosphate under the action of cellular enzymes. Inclusion of acyclovir triphosphate in the chain of viral DNA and subsequent chain termination block further replication of the viral DNA.

    In patients with severe immunodeficiency, prolonged or repeated courses of therapy acyclovir can lead to the emergence of resistant strains, so further treatment with acyclovir may not be effective.In most isolated strains with reduced sensitivity to acyclovir, a relatively low content of viral thymidine kinase was noted, a disruption of the structure of viral thymidine kinase or DNA polymerase.

    The effect of acyclovir on strains of the herpes simplex virus (HSV) in vitro can also lead to the formation of less sensitive strains. There was no correlation between the sensitivity of strains of the herpes simplex virus (HSV) to acyclovir in vitro and clinical efficacy of the drug.

    It was shown that high doses of acyclovir, in the dosage form of lyophilizate for the preparation of a solution for infusions, reduce the incidence and delay the development of CMV infection. Gels after the infusion therapy with acyclovir in high doses are treated with the drug for oral administration at high doses for 6 months, then the mortality and frequency of viremia develop.

    Pharmacokinetics:

    Suction

    In adults, the maximum equilibrium concentrations (Cssmax) Acyclovir one hour after the infusion at a dose of 2.5 mg / kg, 5 mg / kg, 10 mg / kg and 15 mg / kg was 22.7 μmol (5.1 μg / ml); 43.6 μmol (9.8 μg / ml); 92 μmol (20.7 μg / ml) and 105 μmol (23.6 μg / ml), respectively. Minimum equilibrium drug concentrations in plasma (Cssmin) 7 hours after the infusion, respectively, equaled 2.2 μmol (0.5 μg / ml); 3.1 μmol (0.7 μg / ml); 10.2 μmol (2.3 μg / ml) and 8.8 μmol (2.0 μg / ml). In children older than 1 year, similar Cssmax and Cssmin were observed when administered at a dose of 250 mg / m2 instead of 5 mg / kg (dose for adults) and at a dose of 500 mg / m2 instead of 10 mg / kg (dose for adults). In newborns (from 0 to 3 months), which acyclovir was administered as an infusion at a dose of 10 mg / kg for more than one hour every 8 hours CssmOh was 61.2 μmol (13.8 μg / ml), a Cssmin was 10.1 μmol (2.3 μg / ml).

    Distribution

    The concentration of acyclovir in the cerebrospinal fluid is approximately 50% of its concentration in the plasma.

    With blood plasma proteins acyclovir is bound to an insignificant degree (9-33%), therefore, drug interactions due to displacement from the sites of binding to plasma proteins are unlikely.

    Excretion

    In adults, after intravenous administration of acyclovir, the half-life of plasma is about 2.9 hours. Most of the drug is excreted by the kidneys unchanged. Renal clearance of acyclovir significantly exceeds the creatinine clearance, which indicates the excretion of acyclovir by not only glomerular filtration, but also tubular secretion.The main metabolite of acyclovir is 9-carboxymstoxy-methylguanine, which accounts for about 10-15% of the administered dose in urine. In the appointment of acyclovir 1 h after receiving 1 g of probenecid, the half-life of acyclovir and AUC (the area under the concentration-time curve) increased by 18 and 40%, respectively.

    Special patient groups

    In elderly people, the clearance of acyclovir decreases with age, in parallel with the decrease in creatinine clearance, but the half-life of acyclovir changes insignificantly.

    In patients with chronic renal insufficiency, the half-life of acyclovir averaged 19.5 hours, with hemodialysis the mean half-life of acyclovir was 5.7 hours, and the concentration of acyclovir in plasma decreased by approximately 60%.

    Indications:

    - Treatment of infections caused by the herpes simplex virus (HSV)

    - Prevention of infections caused by the herpes simplex virus (HSV), in patients with immunodeficiency

    - Treatment of infections caused by varicella zoster virus (VZV, Varicella zoster virus), including chicken pox and herpes zoster

    - Treatment of infections caused by the herpes simplex virus (HSV) in newborns

    - Prevention of cytomegalovirus infection (CMV) in bone marrow transplant recipients.

    Contraindications:

    Hypersensitivity to acyclovir or valaciclovir or any other component of the drug.

    Carefully:

    - With dehydration, renal failure, neurological disorders, during the development of reactions to cytotoxic drugs (with their intravenous administration) and in the presence of those in the anamnesis, during pregnancy and during breastfeeding.

    - apply acyclovir, lyophilizate for the preparation of a solution for infusions with drugs that disrupt kidney function (for example, ciclosporin, tacrolimus). With their simultaneous application of kidney function monitoring is necessary.

    Pregnancy and lactation:

    Fertility

    There is no evidence of the effect of acyclovir on fertility.

    Pregnancy

    When using acyclovir during pregnancy, there was no increase in the number of birth defects in newborns compared with the general population. However, care should be taken when applying the drug to women during pregnancy and to assess the estimated benefit to the mother and the possible risk to the fetus.

    Breast-feeding

    After taking acyclovir orally at a dose of 200 mg 5 times per day, it was determined in breast milk in concentrations ranging from 60% to 410% of plasma concentrations.At such concentrations in breast milk, breastfed infants may receive acyclovir in a dose up to 0.3 mg / kg / day. Given this fact, caution should be exercised when administering acyclovir to lactating women.

    If you need to use the drug during lactation at the time of treatment should stop breastfeeding.

    Dosing and Administration:

    Adults

    For patients with obesity, the dose should be calculated from the ideal body weight, rather than from the actual body weight of the patient.

    Treatment of infections caused by herpes simplex viruses (HSV, with the exception of herpetic encephalitis) and the virus of chickenpox and herpes zoster (VZV).

    Intravenous infusions in a dose of 5 mg / kg every 8 hours.

    Treatment of infections caused by VZV, and herpetic encephalitis in patients with immunodeficiency.

    Intravenous infusions at a dose of 10 mg / kg every 8 hours with normal kidney function.

    Prevention of CMV infection in bone marrow transplantation.

    500 mg / m2 intravenously 3 times a day with an interval of 8 hours. The duration of treatment is from 5 days to transplantation and up to 30 days after transplantation.

    Children

    In newborn doses are calculated depending on the body weight. With infections, caused by HSV, a dose of 10 mg / kg is recommended every 8 hours.

    Doses of acyclovir for intravenous infusions in children aged 3 months to 12 years are calculated depending on the body surface area.

    Treatment of infection caused by HSV (other than herpetic encephalitis) and VZV.

    Intravenous infusions in a dose of 250 mg / m2 every 8 hours.

    Treatment of herpetic encephalitis and infections caused by WBC in children with immunodeficiency.

    Intravenous infusions in a dose of 500 mg / m2 every 8 hours with normal kidney function.

    Prevention of CMV infection in children older than 2 years.

    Few data suggest that children older than 2 years who have undergone bone marrow transplantation can be assigned an adult dose of acyclovir, a lyophilizate for the preparation of a solution for infusions.

    Children with reduced renal function require a dose adjustment in accordance with the degree of renal failure.

    Elderly patients

    It is necessary to take into account the possibility of renal failure in elderly patients, the doses should be adjusted in accordance with the degree of renal failure.It is necessary to ensure the maintenance of an adequate water balance.

    Patients with renal insufficiency

    Intravenous infusions of acyclovir should be administered with caution in patients with renal insufficiency. The following scheme of correction of doses is proposed depending on the degree of decrease in creatinine clearance:

    Creatinine clearance

    Doses

    25-50 ml / min

    5-10 mg / kg every 12 hours

    10-25 ml / min

    5-10 mg / kg every 24 hours

    0 (anuria-) - 10 ml / min

    With continuous ambulatory peritoneal dialysis, 5-10 mg / kg every 24 hours.

    With hemodialysis, 5-10 mg / kg every 24 hours and after dialysis.

    The course of treatment with acyclovir in the form of intravenous infusions is usually 5 days, but may vary depending on the patient's condition and response to therapy.

    The duration of the preventive use of acyclovir for intravenous infusions is determined by the duration of the period when there is a risk of infection.

    Preparation of solution and method of administration.

    Recommended The dose of acyclovir should be administered as a slow intravenous infusion for 1 hour.

    10 ml of the dilution solution (water for injection or sodium chloride solution for injection (0.9%)) is used to prepare the solution acyclovir with a content of 1 ml of the resulting solution of 25 mg of acyclovir.

    The recommended volume of dilution solution must be added to the powder bottle of the preparation Acyclovir, shake gently until the contents of the vial completely dissolve.

    After dilution, the solution of acyclovir can be administered as an intravenous infusion with the help of a special infusion pump that regulates the rate of administration of the drug.

    Another method of infusion administration is possible when the prepared solution of acyclovir is diluted further to obtain an acyclovir concentration not exceeding 5 mg / ml (0.5%).

    To do this, add the prepared solution to the selected infusion solution, which is recommended below, and shake well until the solutions are completely mixed.

    For children and newborns who need to enter minimal infusion volumes, it is recommended to add 4 ml of the prepared aciclovir solution (100 mg of acyclovir) to 20 ml of the solvent.

    For adults, it is recommended to use infusion solutions in packs of 100 ml, even if this gives the concentration of acyclovir significantly below 0.5 %. Thus, one 100 ml infusion solution can be used for any dose of acyclovir between 250 mg and 500 mg (10 and 20 ml diluted solution). For doses between 500 and 1000 mg of acyclovir, another solution for infusion of this volume (100 ml) should be used.

    Acyclovir, a lyophilizate for the preparation of a solution for infusions, is compatible with the following infusion solutions and remains diluted with them for 12 hours at room temperature (from 15 0 C to 25 ° C):

    - Sodium chloride for intravenous infusions (0.45% and 0.9%)

    - Hatria chloride (0.18%) and glucose (4%) for intravenous infusions

    - Sodium chloride (0.45%) and glucose (2.5%) for intravenous infusions

    - Hartman's solution.

    Since no antibacterial preservative is included in the solution, Dissolution and dilution should be carried out completely in aseptic conditions immediately prior to administration of the preparation. The unused solution is destroyed. If the solution is cloudy or the crystals fall out, it must be destroyed.
    Side effects:

    The adverse events presented below are listed according to anatomophysiological classification and frequency of occurrence.Frequency of occurrence is defined as follows: Often (>1/10), often (> 1/100 and <1/10), infrequently (> 1 / 1,000 and <1/100), rarely (> 1/10 000 and <1/1 000), rarely (<1/10 000, including individual cases).

    On the part of the blood and lymphatic system

    Infrequently: decrease in the content of formed elements of blood (anemia, thrombocytopenia, leukopenia).

    From the immune system

    Rarely: anaphylaxis.

    From the central nervous system

    Rarely: headache, dizziness, agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, drowsiness, encephalopathy, coma.

    The above phenomena were usually observed in patients with impaired renal function and other predisposing factors and, as a rule, were reversible.

    From the side of the vascular system

    Often: phlebitis.

    From the respiratory system

    Rarely: dyspnea.

    From the gastrointestinal tract

    Often: nausea, vomiting.

    Rarely: diarrhea, abdominal pain.

    From the liver and biliary tract

    Often: reversible increase in the activity of liver enzymes.

    Rarely: reversible increase in bilirubin concentration, jaundice, hepatitis.

    From the skin and subcutaneous fat

    Often: itching, hives, rashes (including photosensitivity)

    Rarely: angioedema.

    From the side of the kidneys and urinary tract

    Purely: increased urea and creatinine concentrations at blood. This complication depends on the maximum plasma concentration of the drug and the state of the patient's water balance. To avoid these phenomena, you should prescribe a slow infusion for 1 hour.

    Rarely: impaired renal function, acute renal failure, pain in the projection of the kidneys.

    Pain in the projection of the kidneys can be associated with impaired renal function. It is necessary to ensure adequate maintenance of water-salt metabolism of the body. Renal failure, which develops during the treatment with acyclovir, is usually quickly eliminated by rehydrating patients and / or decreasing the dose of the drug or canceling it. Progression to acute renal failure occurs in extremely rare cases.

    General and local reactions

    Rarely: general weakness, fever, local inflammatory reactions.

    Severe local inflammatory reactions, sometimes leading to skin damage, may occur if acyclovir is randomly introduced into the extracellular space with intravenous infusion.

    Overdose:

    Symptoms: Neurological symptoms include confusion, hallucinations, agitation, convulsions and coma. Overdoses of acyclovir, lyophilizate for the preparation of a solution for infusion, cause an increase in serum creatinine, blood urea nitrogen and renal failure.

    Treatment: hemodialysis significantly increases the excretion of acyclovir from the blood, therefore it is indicated with an overdose of acyclovir.

    Interaction:

    No clinically relevant interactions were observed with acyclovir ns. Acyclovir is excreted unchanged through the kidneys through active tubular secretion. All drugs with a similar elimination route can increase the plasma concentration of acyclovir. Thus, probenecid and cimetidine increase the AUC (area under the curve "concentration - time") of acyclovir and reduce its renal clearance. However, dose adjustment is not required due to a wide range of therapeutic doses of acyclovir.

    In patients receiving acyclovir, a lyophilizate for preparation of solution for infusion, caution is needed when prescribing with it drugs competing for the path elimination due to the potential increase in plasma concentrations of one, both drugs or their metabolites. The combined use of acyclovir and mycophenolate mofetil (an immunosuppressive drug) used in organ transplantation leads to an increase in the index AUC for acyclovir and an inactive metabolite of mycophenolate mofetil.

    Special instructions:

    Acyclovir is excreted through the kidneys, so patients with renal insufficiency should be administered a reduced dose of the drug. In elderly patients, kidney function may be reduced, so the need to reduce the dose should be evaluated. As for elderly patients, and for patients with renal insufficiency, the risk of developing unwanted reactions from the central nervous system is increased, so these patients should be under close medical supervision to detect symptoms in time. According to reports of these undesirable reactions, they are usually reversible and stop when the drug is discontinued.

    A prolonged or repeated course of treatment with acyclovir in patients with weakened immunity can lead to the appearance of strains of the virus with a decreased sensitivity,which may not respond to treatment with acyclovir.

    In patients receiving acyclovir, lyophilizate for the preparation of a solution for infusions, in high doses (for example, in herpetic encephalitis), renal function should be closely monitored, especially against dehydration or already existing renal failure.

    The prepared acyclovir solution has pH 11.0, so it can not be used inside.

    Effect on the ability to drive transp. cf. and fur:

    Acyclovir, a lyophilizate for the preparation of a solution for infusion, is intended for use only in a hospital environment, so there is no evidence of the effect of the drug on the ability to drive and / or other mechanisms.

    Form release / dosage:

    Lyophilizate for the preparation of a solution for infusions 250 mg.

    Packaging:

    250 mg, in acyclovir, in vials of colorless transparent glass (neutral glass, class 1), sealed with a rubber stopper, crimped with an aluminum cap with a plastic lining.

    Each bottle is labeled or labeled with a quick-fixing paint.

    For 10 bottles per tray of PVC, 1 tray along with the instructions for use are placed in a pack of cardboard.

    Or 5 bottles along with the instructions for use are placed in a cardboard box with an integrated cardboard separator.

    Or one bottle with instructions for use is put in a cardboard box.

    Storage conditions:

    In the dark place at a temperature of ns above 25 ° C. Keep out of the reach of children.

    Shelf life:

    2 years. Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002876
    Date of registration:24.02.2015
    Expiration Date:24.02.2020
    The owner of the registration certificate:ALVILS, LTD. ALVILS, LTD. Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.09.2017
    Illustrated instructions
      Instructions
      Up